A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)

MERCK SERONO S.A.,0 个研究点目标入组 0 人开始时间: 2010年12月6日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 16 至 100（—）

入选标准

•Diagnosis of SLE satisfying at least 4 out of the 11 ACR criteria at the time of diagnosis, with a disease duration of at least six months.
•Active SLE with at least one BILAG A or B score at initial screening (excluding a single B due to haematological values) requiring a change in the dose of corticosteroids.
•Positive antinuclear antibody (ANA) test results (HEp-2 ANA =1:80 and/or anti dsDNA =30 IU/mL) (subjects will be tested at screening).
•Male or female =16 years of age.
•Written informed consent, given before any study-related procedure. Subjects must have read and understood the Informed Consent Form, must fully understand the requirements of the study and must be willing to comply with all study visits and assessments. For subjects under the age of legal majority (according to local law), the subject and a legal guardian must read and sign the informed consent.
•Female subjects must be willing to avoid pregnancy by using an adequate method of contraception for 4 weeks prior to Study Day 1, during the trial and 24 weeks after the last dose of study medication. This requirement does not apply to surgically sterile subjects or to subjects who are post-menopausal for at least 2 years. Adequate contraception is defined as two barrier methods, or one barrier method with a spermicide, or an intrauterine device or use of a female hormonal contraceptive.
•Women of childbearing potential must have a negative serum pregnancy test at initial screening and at the end of screening before dosing. For the purpose of this study, women of childbearing potential are defined as all female subjects after puberty unless they are post-menopausal for at least 2 years or surgically sterile.
•Improvement of the qualifying BILAG A or B flare to BILAG C or D within 10 weeks after commencing steroid treatment.
•Use of an appropriate steroid regimen for the qualifying flare during the screening period, with stability of the dose at 7.5 mg of prednisone or equivalent for 2 weeks after improvement to BILAG C or D.
•No other new BILAG A or B at an assessment performed following confirmation of stable steroid dose.

排除标准

•Any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that constitutes a risk or a contraindication for participation to the study in the opinion of the Investigator or that could interfere with study objectives, conduct or evaluation.
•Active moderate to severe glomerulonephritis
•Active central nervous system SLE deemed to be severe or progressive and/or associated with significant cognitive impairment leading to inability to provide informed consent and/or comply with the protocol.
•Comorbidities requiring systemic corticosteroid therapy (such as asthma or inflammatory bowel disease) and/or preventing engagement in study conduct.
•Any history of treatment with rituximab, abatacept or belimumab.
•Introduction of azathioprine, hydroxychloroquine, chloroquine, or methotrexate within 2 months before initial screening or increase in the dose regimen of any of these medications within 2 months before initial screening.
•Initiation of any immunosuppressive drug within 3 months before initial screening.
•Participation in any interventional clinical trial within the last 28 days or within 5 half-lives of the investigated compound (whichever is longer) before initial screening.
•Treatment with cyclophosphamide mycophenolate mofetil or a calcineurin inhibitor within 3 months before initial screening.
•Treatment with leflunomide, 6-mercaptopurine or thalidomide within 3 months before initial screening.
•Active infection with herpes zoster or Epstein-Barr virus at initial screening.
•Positive HIV serology (subjects will be tested at screening).
•Positive hepatitis B surface antigen (HBsAg) or hepatitis C serology (subjects will be tested at screening).
•History or presence of tuberculosis infection without documentation of adequate treatment, or treatment that occurred in the past year. Subjects should be evaluated and screened for tuberculosis according to national or local recommendations.
•Known active clinically significant acute or chronic infection, or any major episode of infection requiring hospitalisation or treatment with parenteral anti-infectives within 4 weeks of baseline or completion of oral anti-infectives within 2 weeks prior to screening.
•Diagnosis or family history of Creutzfeldt-Jakob disease (CJD).
•History or presence of uncontrolled or New York Heart Association (NYHA) class 3 or 4 congestive heart failure.
•History of cancer, except for adequately treated basal cell carcinoma of the skin, cervical dysplasia or carcinoma in situ of the skin or the cervix.
•Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (AP) level > 2.5 x ULN, or total bilirubin > 1.5 x ULN.
•Clinically significant abnormality in any haematological test (e.g. haemoglobin < 5.5 mmol/L, WBC < 2.5 x 10^9/L, platelets < 75 x 10^9/L) unless attributable to active SLE.
•Serum immunoglobulin G below 6 g/L.
•Clinically significant abnormality on chest X-ray performed within 3 months of initial screening or on ECGs performed at initial screening unless attributable to active SLE.
•Hypersensitivity to any of the components of the formulated atacicept.
•Immunisation with live vaccines or Ig treatment within 1 month before Study Day 1.
•Planned major surgery during the trial period (including follow-up).

研究者

发起方

MERCK SERONO S.A.,

相似试验

进行中（未招募）

1 期

Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate CancerMetastatic castration-resistant prostate cancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-002011-10-ITASTRAZENECA AB720

进行中（未招募）

1 期

A Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 in Participants with Heart Failure with Left Ventricular Ejection Fraction > 40%Heart Failure with Left Ventricular Ejection Fraction > 40%MedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849

EUCTR2020-005844-47-SEAstraZeneca AB1,480

进行中（未招募）

1 期

EUCTR2020-005844-47-SKAstraZeneca AB1,480

进行中（未招募）

1 期

EUCTR2020-005844-47-NLAstraZeneca AB1,480

进行中（未招募）

1 期

Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate CancerMetastatic castration-resistant prostate cancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-002011-10-FRAstraZeneca AB720